Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy

Abstract

Purpose Several studies report an association of sarcopenia with survival in oncologic patients. The aim of this study is to assess the influence of sarcopenia on overall survival (OS) in patients with colorectal liver metastases undergoing interstitial brachytherapy (iBT)

Methods We identified 144 patients with colorectal liver metastases from our database from 2014–2017. Computed tomography (CT) chest scans at the L3 level were retrospectively analyzed. Psoas muscle area (PMA), psoas muscle index (PMI), and skeletal muscle gauge (SMG) were measured on the CT scan before treatment. Parameters were associated with overall survival.

Results 116 patients were included. Median overall survival was 27 months. Median PMA was 13.79 cm², median PMI 4.51 cm²/m². Neither PMA (HR 1.036, 95 % CI 0.996–1.078, p = 0.080), PMI (HR 1.068, 95 % CI 0.922–1.238, p = 0.382), nor SMG (HR 1.00, 95 % CI 0.998–1.003, p = 0.955) were significantly associated with overall survival.

Conclusion Sarcopenic patients undergoing iBT for colorectal liver metastases did not show decreased overall survival. If confirmed by comparative studies, sarcopenia may serve as a biomarker for treatment decision in patients with CRLM.

Key points: Sarcopenia is not a risk factor for survival in patients with CLRM undergoing iBT.

Citation Format

• Thormann M, Heitmann F, Wrobel V et al. Sarcopenia does not limit overall survival in patients with colorectal liver metastases undergoing interstitial brachytherapy. Fortschr Röntgenstr 2023; 195: 217 – 223

Zusammenfassung

Ziel Mehrere Studien zeigen einen Einfluss von Sarkopenie auf das Überleben bei Krebspatienten. Ziel dieser Arbeit war die Untersuchung des Einflusses von Sarkopenie auf das Überleben bei Patienten mit kolorektalen Lebermetastasen vor interstitieller Brachytherapie (iBT).

Material und Methoden Retrospektiv wurden die Daten von 144 Patienten analysiert, die zwischen 2014 und 2017 eine interstitielle Brachytherapie bei kolorektalen Lebermetastasen in unserem Zentrum erhielten. Wir verwendeten die präinterventionelle Computertomografie (CT) auf Höhe L3 zur Bestimmung der psoas muscle area (PMA), des psoas muscle index (PMI) und des skeletal muscle gauge (SMG). Der Zusammenhang zwischen diesen Parametern und dem Überleben wurde untersucht.

Ergebnisse Insgesamt wurden 116 Patienten in die Analyse eingeschlossen. Das mediane Überleben betrug 27 Monate. Der mediane PMA war 13.79 cm², der mediane PMI 4.51 cm²/m². Weder PMA HR 1.036, 95 % CI 0.996–1.078, p = 0.080) noch PMI (HR 1.068, 95 % CI 0.922–1.238, p = 0.382) oder SMG (HR 1.00, 95 % CI 0.998–1.003, p = 0.955) korrelierten signifikant mit dem Überleben.

Schlussfolgerung Bei Patienten mit kolorektalen Lebermetastasen vor iBT zeigte Sarkopenie keinen Einfluss auf das Überleben. Wenn dies durch vergleichende Studien bestätigt wird, könnte die Sarkopenie als ein Biomarker für die Behandlungsentscheidung bei Patienten mit CRLM dienen.

Kernaussagen: Sarkopenie zeigt bei Patienten mit kolorektalen Lebermetastasen vor iBT keinen negativen Einfluss auf das Überleben.

Key words

colorectal cancer - interstitial brachytherapy - overall survival - sarcopenia

Publication History

Received: 24 March 2022

Accepted: 17 August 2022

Article published online:
25 October 2022

• References

• 1 Gini A, Jansen EEL, Zielonke N. et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. Eur J Cancer 2020; 127: 224-235
• 2 Piawah S, Venook AP. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. Cancer 2019; 125: 4139-4147
• 3 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
• 4 Tanis E, Nordlinger B, Mauer M. et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50: 912-919
• 5 Shady W, Petre EN, Gonen M. et al. Percutaneous Radiofrequency Ablation of Colorectal Cancer Liver Metastases: Factors Affecting Outcomes – A 10-year Experience at a Single Center. Radiology 2016; 278: 601
• 6 Jiang C, Davalos RV, Bischof JC. A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans Biomed Eng 2015; 62: 4-20
• 7 Van Hazel GA, Heinemann V, Sharma NK. et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016; 34: 1723-1731
• 8 Collettini F, Lutter A, Schnapauff D. et al. Unresectable Colorectal Liver Metastases: Percutaneous Ablation Using CT-Guided High-Dose-Rate Brachytherapy (CT-HDBRT). RöFo – Fortschritte auf dem Gebiet der Röntgenstrahlen und der Bildgeb. Verfahren 2014; 186: 606-612
• 9 Cruz-Jentoft AJ, Bahat G, Bauer J. et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31
• 10 Gu DH, Kim MY, Seo YS. et al. Clinical usefulness of psoas muscle thickness for the diagnosis of sarcopenia in patients with liver cirrhosis. Clin Mol Hepatol 2018; 24: 319-330
• 11 Bak SH, Kwon SO, Han SS. et al. Computed tomography-derived area and density of pectoralis muscle associated disease severity and longitudinal changes in chronic obstructive pulmonary disease: a case control study. Respir Res 2019; 20: 226
• 12 Shachar SS, Deal AM, Weinberg M. et al. Body Composition as a Predictor of Toxicity in Patients Receiving Anthracycline and Taxane-Based Chemotherapy for Early-Stage Breast Cancer. Clin Cancer Res 2017; 23: 3537-3543
• 13 Sun G, Li Y, Peng Y. et al. Can sarcopenia be a predictor of prognosis for patients with non-metastatic colorectal cancer? A systematic review and meta-analysis. Int J Colorectal Dis 2018; 33: 1419-1427
• 14 Deng HY, Zha P, Peng L. et al. Preoperative sarcopenia is a predictor of poor prognosis of esophageal cancer after esophagectomy: a comprehensive systematic review and meta-analysis. Dis Esophagus 2019; 32
• 15 Mintziras I, Miligkos M, Wächter S. et al. Sarcopenia and sarcopenic obesity are significantly associated with poorer overall survival in patients with pancreatic cancer: Systematic review and meta-analysis. Int J Surg 2018; 59: 19-26
• 16 Ricke J, Mohnike K, Pech M. et al. Local Response and Impact on Survival After Local Ablation of Liver Metastases From Colorectal Carcinoma by Computed Tomography–Guided High-Dose-Rate Brachytherapy. Int J Radiat Oncol 2010; 78: 479-485
• 17 Seidensticker R, Damm R, Enge J. et al. Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival. BMC Cancer 2018; 18: 882
• 18 Bahat G, Turkmen BO, Aliyev S. et al. Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass. Clin Nutr 2021; 40: 4360-4365
• 19 Pratesi A. Skeletal muscle: an endocrine organ. Clin CASES Miner BONE Metab 2013; 10: 11-14
• 20 Pin F, Couch ME, Bonetto A. Preservation of muscle mass as a strategy to reduce the toxic effects of cancer chemotherapy on body composition. Curr Opin Support Palliat Care 2018; 12: 420-426
• 21 Deng H-Y, Hou L, Zha P. et al. Sarcopenia is an independent unfavorable prognostic factor of non-small cell lung cancer after surgical resection: A comprehensive systematic review and meta-analysis. Eur J Surg Oncol 2019; 45: 728-735
• 22 Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: A comprehensive review. World J Clin Cases 2020; 8: 1188-1202
• 23 Murachi Y, Sakai D, Koseki J. et al. Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib. Int J Clin Oncol 2021; 26: 409-416
• 24 van Vledder MG, Levolger S, Ayez N. et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases19. Br J Surg 2012; 99: 550-557
• 25 Trejo-Avila M, Bozada-Gutiérrez K, Valenzuela-Salazar C. et al. Sarcopenia predicts worse postoperative outcomes and decreased survival rates in patients with colorectal cancer: a systematic review and meta-analysis. Int J Colorectal Dis 2021; 36: 1077-1096
• 26 Peng PD, van Vledder MG, Tsai S. et al. Sarcopenia negatively impacts short-term outcomes in patients undergoing hepatic resection for colorectal liver metastasis. HPB 2011; 13: 439-446
• 27 Lodewick TM, Van Nijnatten TJA, Van Dam RM. et al. Are sarcopenia, obesity and sarcopenic obesity predictive of outcome in patients with colorectal liver metastases?. HPB (Oxford) 2015; 17: 438-446
• 28 Dodson RM, Firoozmand A, Hyder O. et al. Impact of Sarcopenia on Outcomes Following Intra-arterial Therapy of Hepatic Malignancies. J Gastrointest Surg 2013; 17: 2123-2132
• 29 Fujita M, Takahashi A, Hayashi M. et al. Skeletal muscle volume loss during transarterial chemoembolization predicts poor prognosis in patients with hepatocellular carcinoma. Hepatol Res 2019; 49: 778-786
• 30 Loosen SH, Schulze-Hagen M, Bruners P. et al. Sarcopenia Is a Negative Prognostic Factor in Patients Undergoing Transarterial Chemoembolization (TACE) for Hepatic Malignancies. Cancers 2019; 11: 1503
• 31 Iritani S, Imai K, Takai K. et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol 2015; 50: 323-332
• 32 Fujiwara N, Nakagawa H, Kudo Y. et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015; 63: 131-140
• 33 Salman A, Salman M, Moustafa A. et al. Impact of Sarcopenia on Two-Year Mortality in Patients with HCV-Associated Hepatocellular Carcinoma After Radiofrequency Ablation. J Hepatocell Carcinoma 2021; 8: 313-320